Chicago Outdoor Fitness and Dance Festival promotes healthier lifestyle
It's the second year for the Chicago Outdoor Fitness and Dance Festival, with the goal being to promote wellness on all fronts.
Walk faster, feel better — and more health headlines
'This isn't about fitness. This isn't about dance. It's about the overall health,' Jon Calhoun with Pit Fitness Development and Training said. 'One, the mental health. There are a lot of components that go into mental health, and we believe that dance, movement and fitness help captivate that approach with a stronger mind and mentality for whatever goals you got going on.'
A Harvard study showed 15 minutes of running or walking a day cut the risk of major depression by 26%.
This festival looks to help by starting a healthier lifestyle while taking in the vibes of Chicago's Far South Side.
Read more: Latest Chicago news and headlines
'The importance of fitness, the importance of gathering together. Just a peaceful environment where we can celebrate each other and have fun,' Katrina Dillard of the Chicago Outdoor Fitness and Dance Festival said. 'It opens up my heart meeting different people from the neighborhood, our elders. It really opens up my heart just to hear their stories and their background and how long they've been here and have never seen this before, so it's amazing.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings
July 22 - UnitedHealth Group (NYSE:UNH) has tumbled roughly 42% year?to?date, driven by rising Medicare Advantage costs, a surprise CEO exit, withdrawn guidance and a Department of Justice probe. However, ahead of its July 29 Q2 earnings, Bernstein analyst Lance Wilkes tapped UNH as a 'Top Pick,' saying the pullback creates an attractive entry point. He noted the stock trades at about 13.5 times forward earnings, below its ten?year average. Warning! GuruFocus has detected 4 Warning Sign with UNH. Wilkes cut his 2025 EPS estimate by 10% to reflect reserve strengthening and cost pressures in individual and Medicaid segments, plus a cleanup of OptumHealth risk contracts. Yet he projects earnings per share could double by 2029, implying a 19% compound annual growth rate. The analyst expects cost normalization to begin in Medicaid in Q3 and in Medicare Advantage in early 2026 as utilization patterns stabilize. He also highlighted a hardening pricing environment for government managed?care plans as a margin tailwind. Is UNH Stock a Buy? Based on the one year price targets offered by 24 analysts, the average target price for UnitedHealth Group Inc is $375.46 with a high estimate of $677.00 and a low estimate of $270.00. The average target implies a upside of +33.08% from the current price of $282.14. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025
MINNEAPOLIS, July 22, 2025--(BUSINESS WIRE)--Sleep Number Corporation (Nasdaq: SNBR) will release its fiscal second quarter results through June 28, 2025, before market open on Wednesday, July 30, 2025. Management will host its regularly scheduled conference call to discuss the company's results at 8:30 a.m. EDT (7:30 a.m. CDT; 5:30 a.m. PDT). To access the webcast, please visit the investor relations area of the Sleep Number website at The webcast replay will remain available for approximately 60 days. About Sleep Number Corporation Sleep Number is a sleep wellness company. We are guided by our purpose to improve the health and wellbeing of society through higher quality sleep. To date, our innovations have improved nearly 16 million lives. Our sleep wellness platform helps solve sleep problems, whether it's providing individualized temperature control for each sleeper through our Climate360 smart bed or applying our 34 billion hours of longitudinal sleep data and expertise to research with global institutions. Our smart bed ecosystem helps people sleep better by offering adjustable comfort and personalized sleep and health insights. Millions of Smart Sleepers benefit from higher quality sleep, and our 3,400 dedicated team members are passionate about creating innovative solutions through our vertically integrated business model, including direct-to-consumer selling in 630 stores and online. To learn more about life-changing, individualized sleep, visit a Sleep Number® store near you, our newsroom and investor relations sites, or View source version on Contacts Investor Contact investorrelations@ Media Contact Muriel Lussier, Sleep Number Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ('Senti Bio'), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Senti Bio Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company's wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti's Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships. Availability of Other Information About Senti Biosciences, Inc. For more information, please visit the Senti Bio website at or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website ( including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775SNTI@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
